In our study, we compared the mutation characteristics of several common therapeutic agents of NSCLC treatment in LUSC, like EGFR, ALK, ROS1, BRAF, KARS, RET and MET. And the mutation frequency of ROS1 was the highest among the above genes in LUSC. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.